Danaher Corporation $DHR Shares Sold by Candriam S.C.A.

Candriam S.C.A. cut its stake in shares of Danaher Corporation (NYSE:DHR) by 1.6% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 444,856 shares of the conglomerate’s stock after selling 7,077 shares during the period. Candriam S.C.A. owned approximately 0.06% of Danaher worth $88,197,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of DHR. Sivia Capital Partners LLC lifted its position in shares of Danaher by 6.3% in the 2nd quarter. Sivia Capital Partners LLC now owns 2,009 shares of the conglomerate’s stock valued at $397,000 after acquiring an additional 119 shares in the last quarter. Fifth Third Wealth Advisors LLC boosted its position in shares of Danaher by 4.6% in the second quarter. Fifth Third Wealth Advisors LLC now owns 6,502 shares of the conglomerate’s stock worth $1,284,000 after buying an additional 283 shares during the period. GFS Advisors LLC purchased a new position in shares of Danaher during the second quarter valued at $641,000. Sivik Global Healthcare LLC raised its position in Danaher by 14.3% during the second quarter. Sivik Global Healthcare LLC now owns 40,000 shares of the conglomerate’s stock valued at $7,902,000 after buying an additional 5,000 shares during the period. Finally, Concurrent Investment Advisors LLC lifted its stake in Danaher by 14.0% in the 2nd quarter. Concurrent Investment Advisors LLC now owns 11,459 shares of the conglomerate’s stock worth $2,264,000 after acquiring an additional 1,411 shares in the last quarter. Institutional investors and hedge funds own 79.05% of the company’s stock.

Insider Buying and Selling at Danaher

In other news, Director Teri List sold 3,298 shares of Danaher stock in a transaction dated Tuesday, November 18th. The stock was sold at an average price of $226.50, for a total value of $746,997.00. Following the transaction, the director directly owned 20,762 shares in the company, valued at approximately $4,702,593. The trade was a 13.71% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Brian W. Ellis sold 21,776 shares of the stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $219.23, for a total value of $4,773,952.48. Following the sale, the senior vice president owned 14,553 shares of the company’s stock, valued at approximately $3,190,454.19. The trade was a 59.94% decrease in their position. The SEC filing for this sale provides additional information. Company insiders own 11.20% of the company’s stock.

Danaher Trading Up 0.5%

Danaher stock opened at $216.77 on Monday. Danaher Corporation has a one year low of $171.00 and a one year high of $242.80. The company’s fifty day moving average price is $229.62 and its two-hundred day moving average price is $215.17. The company has a debt-to-equity ratio of 0.35, a current ratio of 1.87 and a quick ratio of 1.51. The company has a market capitalization of $153.12 billion, a price-to-earnings ratio of 43.01, a PEG ratio of 2.93 and a beta of 0.91.

Danaher (NYSE:DHR) last released its quarterly earnings results on Wednesday, January 28th. The conglomerate reported $2.23 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.14 by $0.09. Danaher had a return on equity of 10.81% and a net margin of 14.71%.The company had revenue of $6.84 billion during the quarter, compared to the consensus estimate of $6.79 billion. During the same quarter in the prior year, the company posted $2.14 EPS. The firm’s revenue was up 4.6% on a year-over-year basis. Danaher has set its FY 2026 guidance at 8.350-8.500 EPS. On average, analysts forecast that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, January 30th. Investors of record on Friday, December 26th were paid a $0.32 dividend. The ex-dividend date was Friday, December 26th. This represents a $1.28 dividend on an annualized basis and a yield of 0.6%. Danaher’s dividend payout ratio (DPR) is presently 25.40%.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on DHR shares. Morgan Stanley began coverage on Danaher in a research note on Monday, December 1st. They set an “overweight” rating and a $270.00 target price on the stock. Jefferies Financial Group boosted their price objective on shares of Danaher from $255.00 to $265.00 and gave the company a “buy” rating in a research report on Wednesday, January 28th. Barclays increased their target price on shares of Danaher from $225.00 to $250.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 22nd. Leerink Partners upped their price target on shares of Danaher from $260.00 to $270.00 and gave the stock an “outperform” rating in a research note on Friday, January 16th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Danaher in a research note on Monday, December 29th. Twenty analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat, Danaher has a consensus rating of “Moderate Buy” and a consensus target price of $253.86.

Danaher Company Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.